ALGS Earnings Aligos Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–23 of 23
| Q2 2026 | 2026-06-30 | -0.14 | 2026-08-06 | 10-Q |
| Q1 2026 | 2026-03-31 | -2.21 | 2026-05-07 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | 4.23 | 2026-03-05 | 10-K |
| FY 2025 | 2025-12-31 | -2.45 | 2026-03-05 | 10-K |
| Q3 2025 | 2025-09-30 | -3.04 | 2025-11-06 | 10-Q |
| Q2 2025 | 2025-06-30 | -1.53 | 2025-08-06 | 10-Q |
| Q1 2025 | 2025-03-31 | -2.11 | 2025-05-06 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | -13.10 | 2025-03-10 | 10-K |
| FY 2024 | 2024-12-31 | -20.94 | 2025-03-10 | 10-K |
| Q3 2024 | 2024-09-30 | -3.07 | 2024-11-06 | 10-Q |
| Q2 2024 | 2024-06-30 | 0.81 | 2024-08-06 | 10-Q |
| Q1 2024 | 2024-03-31 | -5.58 | 2024-05-07 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | 0.17 | 2024-03-12 | 10-K |
| FY 2023 | 2023-12-31 | -34.20 | 2024-03-12 | 10-K |
| Q3 2023 | 2023-09-30 | -10.37 | 2023-11-02 | 10-Q |
| Q2 2023 | 2023-06-30 | -10.75 | 2023-08-03 | 10-Q |
| Q1 2023 | 2023-03-31 | -13.25 | 2023-05-04 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | -12.50 | — | — |
| FY 2022 | 2022-12-31 | -56.25 | — | — |
| Q3 2022 | 2022-09-30 | -11.00 | 2022-11-02 | 10-Q |
| Q2 2022 | 2022-06-30 | -11.75 | — | — |
| Q1 2022 | 2022-03-31 | -21.00 | — | — |
| Q3 2021 | 2021-09-30 | -19.50 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.